Septerna

Septerna is an operating drug discovery company, not an investment firm. Capital allocation decisions are made by CEO Jeffrey Finer and the board, which includes representatives from RA Capital Management and Third Rock Ventures. As a venture-backed biotech, its financing strategy is determined by pipeline milestones and syndicate terms, not by an internal investment committee.

Traditional GPCR drug discovery screens recombinant receptor proteins removed from their cell-membrane environment, which distorts binding-site shape and yields hits that often fail in vivo. Septerna's platform stabilizes receptors in their native complex with G proteins and lipids, then uses cryo-EM and machine learning to screen compound libraries against physiologically relevant conformations. The firm contends this approach unlocks historically intractable GPCRs that have defied small-molecule and antibody campaigns.

Septerna is an operating biotechnology company, not a venture-capital firm or family office. It raises venture financing to fund internal drug discovery programs, maintains its own laboratory and scientific staff in South San Francisco, and intends to retain development rights on its programs through mid-stage clinical trials before partnering or commercializing independently.

Septerna has not published a formal exclusion list, but its disclosed focus on endocrinology, metabolic disease, and immunology suggests it avoids receptors in areas like oncology or neuroscience where competitive density is extreme or where the platform's structural advantage is less decisive. The firm selects targets based on validation data, structural feasibility via cryo-EM, and the absence of solved drug-discovery campaigns by competitors.

Robert Lefkowitz is a co-founder of Septerna and won the 2012 Nobel Prize in Chemistry for his work on GPCR structure and function. His Duke University laboratory provided key structural insights and founding intellectual property, but Septerna operates independently as a venture-backed company. The relationship influences the firm's scientific advisory network and recruitment but does not entail ongoing research obligations or royalty claims beyond standard licensing.

Septerna has not syndicated its discovery-stage programs with pharmaceutical partners, preferring to advance assets internally through IND filings. The firm has stated it will evaluate strategic partnerships once it possesses Phase 1 clinical data, a model that mirrors precision platform biotechs like Relay Therapeutics and Kymera before their first major pharma deals.

RA Capital Management led the $150 million Series B and joins Third Rock Ventures, which seeded the firm, as the two most influential venture backers. Both firms are known for long development timelines and board-level involvement in pipeline decisions, suggesting Septerna will face disciplined governance in decisions about which programs advance to clinical trials, who leads them, and when to consider partnering.